Just presented at #ESMO2026 by Prof @ALEDIGNUS12
🔬 ET-FES study: whole-body ER heterogeneity on ¹⁸F-FES PET/CT independently predicts worse survival in ER+/HER2- MBC
📊 Median OS 42.5 vs 69.6 months
📈 Adjusted HR 2.08 (p=.007)
Proud to share these results with ET-FES Group
28 views · 0 likes · 1 repost · 1 reply
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org- Simone Nardin@nardin_simone
@ALEDIGNUS12 @myESMO @oncologia_upo
Source: Simone Nardin · x.com